Home | Contact | Directions
Bookmark and Share

Newsroom

The bromodomain and extra-terminal inhibitor CPI203 enhances the antiproliferative effects of rapamycin on human neuroendocrine tumors

Posted in Constellation in the News, Newsroom

This paper, by Dr. Eugenia Xu and colleagues from the Sackler Foundation and Robert Wood Johnson Medical School and scientists from Constellation Pharmaceuticals, is now available in the open-access journal Cell Death and Disease.

View full paper here

Read more »

Synergistic antitumor activity of lenalidomide with the BET bromodomain inhibitor CPI203 in bortezomib-resistant mantle cell lymphoma

Posted in Constellation in the News, Newsroom

In this paper, Dr. Gael Roué and his colleagues at the IDIBAPS in Barcelona and scientists from Constellation Pharmaceuticals presented evidence of a synergistic anti-tumor activity of lenalidomide in combination with a BET inhibitor in bortezomib-resistant mantle cell lymphoma cell …

Read more »

EZH2 Inhibitor Efficacy in Non-Hodgkin’s Lymphoma Does Not Require Suppression of H3K27 Monomethylation

Posted in Constellation in the News, Newsroom

Our paper “EZH2 Inhibitor Efficacy in Non-Hodgkin’s Lymphoma Does Not Require Suppression of H3K27 Monomethylation” is now available in Cell Press, Chemistry and Biology.

View full paper here

Read more »

Constellation meets contractual milestones and receives balance of $15 million loan

Posted in Constellation in the News, Newsroom

Today, Constellation announced that it has secured a $15 million senior secured loan with Oxford Finance and Silicon Valley Bank.  Constellation had already drawn down $5 million from this facility, which was originally closed back in June of 2013 and,

Read more »

A Practical Synthesis of Indoles via a Pd-Catalyzed C-N Ring Formation

Posted in Constellation in the News, Newsroom

Our paper “A Practical Synthesis of Indoles via a Pd-Catalyzed C-N Ring Formation” is now available in American Chemical Society, Organic Letters.

 

View full paper here

Read more »

Constellation Expands Clinical Studies of CPI-0610

Posted in Constellation in the News, Newsroom

Today, Constellation announced that it has initiated two additional clinical studies of its lead BET Inhibitor, CPI-0610.  CPI-0610 has been progressing in a Phase 1 clinical trial in patients with lymphoma since September of 2013.  As that trial continues, two …

Read more »

Blockade of oncogenic IκB kinase activity in diffuse large B-cell lymphoma by bromodomain and extraterminal domain protein inhibitors

Posted in Constellation in the News, Newsroom

In this paper just published in PNAS, Dr. Lou Staudt and his colleagues at the United States National Cancer Institute and scientists from Constellation Pharmaceuticals demonstrated that combination of the recently approved drug, ibrutinib, with small molecule BET bromodomain inhibitors …

Read more »

Constellation Pharmaceuticals will give a presentation on EZH2 and exhibit posters on EZH2 and BET at the AACR Annual Meeting, April 5-9 in San Diego, CA.

Posted in Constellation in the News, Newsroom

At this year’s AACR Annual Meeting Constellation will be represented by one oral presentation and four posters encompassing work on chromatin biology.

Patrick Trojer will be giving a talk entitled “Targeting Histone Lysine Methylation in Cancer”, in Saturday's 11:45 am …

Read more »

Constellation Pharmaceuticals named one of The Boston Globe’s Top Places to Work 2013

Posted in Constellation in the News, Newsroom

For more information including the full article as well as the list of other employers recognized for this honor click herewww.bostonglobe.com/topplaces.…

Read more »

next »